World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
129
Citations
60264
World Ranking
2601
National Ranking
68

Axel Le Cesne publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Axel Le Cesne sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 784 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Axel Le Cesne D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Axel Le Cesne sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 129 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Axel Le Cesne is affiliated with the Institut Gustave Roussy in France and has contributed extensively to the field of medicine, with a focus on oncology and sarcoma research. Their work spans a range of specialized subfields including pulmonary and respiratory medicine, surgery, rheumatology, and gastroenterology.

The primary area of Axel Le Cesne's research concentrates on sarcoma diagnosis and treatment. Additional key topics of their work include vascular tumors and angiosarcomas, gastrointestinal tumor research and treatment, cardiac tumors and thrombi, gastrointestinal disorders and treatments, gastric cancer management and outcomes, and lymphoma diagnosis and treatment.

Their recent notable publications include:

  • Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas, 2020, JAMA
  • Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network, 2021, PLoS ONE
  • Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network, 2020, Annals of Oncology
  • Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 2020, Cancer

Axel Le Cesne frequently collaborates with several researchers, including:

  • Jean-Yves Blay
  • Nicolas Penel
  • Antoîne Italiano
  • Olivier Mir
  • Emmanuelle Bompas

Their research is often published in journals such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • Clinical Cancer Research
  • European Journal of Cancer

Best Publications

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

    François Ghiringhelli;Cedric Menard;Pierre Emmanuel Puig;Sylvain Ladoire

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

    Isabelle Ray-Coquard;Jean-Yves Blay;Antoine Italiano;Axel Le Cesne

  • Cutaneous side-effects of kinase inhibitors and blocking antibodies

    Caroline Robert;Jean-Charles Soria;Alain Spatz;Axel Le Cesne

  • Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

    George D. Demetri;Sant P. Chawla;Margaret von Mehren;Paul Ritch

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Primary Retroperitoneal Sarcomas: A Multivariate Analysis of Surgical Factors Associated With Local Control

    Sylvie Bonvalot;Michel Rivoire;Marine Castaing;Eberhard Stoeckle

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

    Federica Grosso;Robin L. Jones;George D. Demetri;Ian R. Judson

  • Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

    Penella J. Woll;Peter Reichardt;Axel Le Cesne;Sylvie Bonvalot

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO (vol 16, pg 566, 2005)

    JY Blay;S Bonvalot;P Casali;H Choi

Frequent Co-Authors

Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Antoine Italiano
Antoine Italiano University of Bordeaux
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Christine Chevreau
Christine Chevreau DuPont (United States)
François Bertucci
François Bertucci Aix-Marseille University
Paolo G. Casali
Paolo G. Casali University of Milan
Cécile Le Péchoux
Cécile Le Péchoux Institut Gustave Roussy
Jean-Michel Coindre
Jean-Michel Coindre University of Bordeaux
Alessandro Gronchi
Alessandro Gronchi University of Milan
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always require the traditional medical school route. There are numerous alternative pathways and online degrees that offer rewarding roles in the healthcare field, often with less time and financial commitment.

For those interested in patient care but seeking a faster track, adn nursing programs can be an accessible entry point. These programs typically take two years to complete and are often less competitive for admission.

If required entrance exams are a barrier, you may benefit from considering a nursing school that don't require teas or HESI exams. This can open up more opportunities for aspiring nurses.

Not all healthcare careers involve direct patient care. Those interested in the business side of medicine might explore best online medical billing and coding schools, which train students for vital administrative roles.

If leadership interests you, an accelerated healthcare administration degree can help you quickly move into management positions in hospitals, clinics, and other healthcare settings.

Best Scientists Citing Axel Le Cesne

Trending Scientists

Recently Published Articles